At least a subset of patients with RSV-related lower respiratory tract infection appears to benefit from bronchodilator therapy. A study from 2009 found that a trial with monitoring for effect on respiratory rate, pulse, and oxygenation may be reasonable in selected cases.
Ribavirin, a broad-spectrum antiviral agent, is licensed by the US Food and Drug Administration as an aerosolized treatment option in children with severe RSV infection. However, the use of ribavirin has been limited to life-threatening RSV infections in immunocompromised patients because of its high acquisition cost, lack of demonstrated benefit in decreasing hospitalization or mortality, and concerns regarding patient toxicity as well as healthcare worker safety (owing to mode of administration).
Antibiotics should not be administered to children with RSV unless there is a concomitant bacterial infection.
Learn more about the pharmacologic management of RSV.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Asif Noor. Fast Five Quiz: Pediatric Respiratory Syncytial Virus Management - Medscape - Mar 03, 2022.